SCPH vs. OPTN, CHMA, CMRX, AQST, FBIO, GHRS, HROW, LRMR, ZYME, and ANNX
Should you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include OptiNose (OPTN), Chiasma (CHMA), Chimerix (CMRX), Aquestive Therapeutics (AQST), Fortress Biotech (FBIO), GH Research (GHRS), Harrow (HROW), Larimar Therapeutics (LRMR), Zymeworks (ZYME), and Annexon (ANNX). These companies are all part of the "medical" sector.
scPharmaceuticals (NASDAQ:SCPH) and OptiNose (NASDAQ:OPTN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, community ranking, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
In the previous week, OptiNose had 2 more articles in the media than scPharmaceuticals. MarketBeat recorded 2 mentions for OptiNose and 0 mentions for scPharmaceuticals. OptiNose's average media sentiment score of 1.83 beat scPharmaceuticals' score of 0.00 indicating that OptiNose is being referred to more favorably in the news media.
89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 85.6% of OptiNose shares are owned by institutional investors. 5.5% of scPharmaceuticals shares are owned by insiders. Comparatively, 2.7% of OptiNose shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
OptiNose has a net margin of -41.55% compared to scPharmaceuticals' net margin of -327.29%. OptiNose's return on equity of 0.00% beat scPharmaceuticals' return on equity.
scPharmaceuticals has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, OptiNose has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500.
scPharmaceuticals currently has a consensus price target of $19.00, suggesting a potential upside of 406.67%. OptiNose has a consensus price target of $3.67, suggesting a potential upside of 245.91%. Given scPharmaceuticals' higher probable upside, research analysts clearly believe scPharmaceuticals is more favorable than OptiNose.
OptiNose has higher revenue and earnings than scPharmaceuticals. OptiNose is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
OptiNose received 88 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.24% of users gave scPharmaceuticals an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
Summary
OptiNose beats scPharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get scPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
scPharmaceuticals Competitors List
Related Companies and Tools
